Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 14/20 | 0.53 |
| ▸ | RAB9A | P51151 | 13/20 | 0.53 |
| ▸ | MAPT | P10636 | 9/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | NAMPT | P43490 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | ECE1 | P42892 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL297607 | 0.80 | RAB9A (0.51) | NPC1RAB9AMAPTSMN1; SMN2KDM4E | |
| SCHEMBL2814670 | 0.77 | RAB9A (0.55) | NPC1RAB9AMAPTSMN1; SMN2KDM4E | |
| SCHEMBL924944 | 0.77 | RAB9A (0.55) | NPC1RAB9AMAPTSMN1; SMN2KDM4E | |
| SCHEMBL924866 | 0.76 | NAMPT (0.55) | NPC1RAB9AMAPTSMN1; SMN2KDM4E | |
| SCHEMBL924865 | 0.75 | RAB9A (0.55) | NPC1RAB9AMAPTSMN1; SMN2KDM4E | |
| SCHEMBL297721 | 0.74 | LMNA (0.48) | NPC1RAB9AMAPTSMN1; SMN2POLB | |
| SCHEMBL297279 | 0.73 | MAPT (0.49) | NPC1RAB9AMAPTSMN1; SMN2POLB | |
| SCHEMBL14484167 | 0.73 | RAB9A (0.74) | NPC1RAB9AMAPTSMN1; SMN2KDM4E | |
| SCHEMBL925877 | 0.71 | RAB9A (0.52) | NPC1RAB9AMAPTSMN1; SMN2KDM4E | |
| SCHEMBL3879676 | 0.71 | GRM4 (0.64) | NPC1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1912644-B1 | N-(ARYLALKYL)-1H-PYRROLOPYRIDINE-2-CARBOXAMIDE DERIVATIVES, PREPARATION AND USE THEREOF | SANOFI AVENTIS (FR) | 2009-12-16 | — | — | EP | claimed |
| US-20100249183-A1 | THERAPEUTIC USE OF N-(ARYLALKYL)-1H-PYRROLOPYRIDINE-2-CARBOXAMIDE DERIVATIVES | SANOFI-AVENTIS (FR) | 2010-09-30 | — | — | US | disclosed |
| US-7763636-B2 | N-(arylalkyl)-1H-pyrrolopyridine-2-carboxamide derivatives, preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2010-07-27 | — | — | US | disclosed |
| EP-1912644-B1 | N-(ARYLALKYL)-1H-PYRROLOPYRIDINE-2-CARBOXAMIDE DERIVATIVES, PREPARATION AND USE THEREOF | SANOFI AVENTIS (FR) | 2009-12-16 | — | — | EP | disclosed |
| US-20080125459-A1 | N-(ARYLALKYL)-1H-PYRROLOPYRIDINE-2-CARBOXAMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2008-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125459-A1 | N-(ARYLALKYL)-1H-PYRROLOPYRIDINE-2-CARBOXAMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | CYP3A5, ZYX, ZDHHC2 | NPC1 127/4885RAB9A 1589/4885MAPT 4141/4885 |
| US-20100249183-A1 | THERAPEUTIC USE OF N-(ARYLALKYL)-1H-PYRROLOPYRIDINE-2-CARBOXAMIDE DERIVATIVES | ZDHHC2, ZYX, GLS2 | NPC1 265/4885RAB9A 1911/4885MAPT 3538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.